Earendil faces regulatory scrutiny during Hong Kong IPO process

The Wall Street Journal reports that Earendil, a Chinese AI biotechnology company, has encountered a regulatory hurdle as it pursues a Hong Kong initial public offering. According to the report, Chinese regulators raised concerns about the company's red-chip holding structure after it recently submitted its IPO application.